Caley Castelein, M.D. has served as Chair of our board of directors since August 2021. Since February 2017, Dr. Castelein has served as a member of the board of directors of Aerpio Therapeutics, Inc., a biopharmaceutical company, which merged with Aadi Bioscience, Inc. (NASDAQ: AADI) in August 2021. Since March 2006, he has served as a Managing Director and founder of Kearny Venture Partners, L.P., a healthcare venture capital fund. Additionally, he founded KVP Capital, L.P. in 2013 and manages the fund which invests in small and mid-cap healthcare companies. Dr. Castelein has served as a director at ViewRay, Inc. (NASDAQ: VRAY), a medical device company, since 2008 and NewBridge Pharmaceuticals FZ, LLC, a specialty therapeutics company, since March 2015. He served as a member of the board of directors for Boreal Genomics, Inc., a diagnostics company, from October 2010 until its successful sale in September 2021. Dr. Castelein served as a member of the board of directors for Waterstone Pharmaceuticals, Inc., a pharmaceutical company from March 2015 to March 2018; AliveCor, Inc., a medical device company from April 2015 to March 2020; Wellpartner, Inc., a pharmaceutical distribution solutions company, from March 2015 to November 2017; and Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company from March 2015 to July 2015. He holds an A.B. from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry.
What is Caley Castelein's net worth?
The estimated net worth of Caley Castelein is at least $903,908.25 as of October 27th, 2023. Dr. Castelein owns 516,519 shares of Aadi Bioscience stock worth more than $903,908 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Castelein may own. Learn More about Caley Castelein's net worth.
How do I contact Caley Castelein?
Has Caley Castelein been buying or selling shares of Aadi Bioscience?
Caley Castelein has not been actively trading shares of Aadi Bioscience during the last quarter. Most recently, on Thursday, August 26th, Caley Castelein bought 259,998 shares of Aadi Bioscience stock. The stock was acquired at an average cost of $13.08 per share, with a total value of $3,400,773.84. Learn More on Caley Castelein's trading history.
Are insiders buying or selling shares of Aadi Bioscience?
During the last twelve months, insiders at the sold shares 19 times. They sold a total of 344,180 shares worth more than $1,496,498.12. The most recent insider tranaction occured on April, 1st when Chairman Neil Desai sold 17,772 shares worth more than $41,053.32. Insiders at Aadi Bioscience own 35.8% of the company.
Learn More about insider trades at Aadi Bioscience. Information on this page was last updated on 4/1/2024.
